The counter argument here is GILD is working on the Sofo/GS-5816 combo with the goal of creating a single combo (SOC?) that works in all HCV patients. I'm a strong supporter of the nucleotide class and believe this should be ultimate development goal.
Market Data 
Markets 
AI
